Results 41 to 50 of about 8,348,024 (289)

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial

Haematologica, 2011
This trial evaluated the feasibility and efficacy of the infusion of mesenchymal stem cells expanded using human serum for the treatment of refractory acute or chronic graft-versus-host disease. Twenty-eight expansions were started.
Jose A. Pérez-Simon, Olga López-Villar, Enrique J. Andreu, José Rifón, Sandra Muntion, María Diez Campelo, Fermín M. Sánchez-Guijo, Carmen Martinez, David Valcarcel, Consuelo del Cañizo   +9 more
doaj   +1 more source

Acute Graft-Versus-Host Disease: A Brief Review

Turkish Journal of Hematology, 2020
Graft‐versus‐host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Elifcan Aladağ, Engin Kelkitli, Hakan Göker   +2 more
doaj   +1 more source

Acute Graft-versus-Host Disease of the Gut.

Internal Medicine, 1995
A 28-year-old man with acute promyelocytic leukemia at first early relapse received HLA-matched allogenic bone marrow transplantation (BMT) at first early relapse. Cyclosporin A and methotrexate were administered at conventional doses as a prophylaxis for graft-versus-host disease (GVHD).
IZUMI, Tohru, AMEMIYA, Youichi, IWAO, Noriaki, SUZUKI, Toshiyuki, MUROI, Kazuo, YOSHIDA, Minoru, HATAKE, Kiyohiko, MIURA, Yasusada, HITOMI, Noribumi, HATAKEYAMA, Makio, NAKAZAWA, Kenji, SAITO, Ken   +11 more
openaire   +3 more sources

Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells

Haematologica, 2013
Despite advances in immunosuppressive regimens, acute graft-versus-host disease remains a frequent complication of allogeneic hematopoietic cell transplantation.
Anne-Kathrin Hechinger, Kristina Maas, Christoph Dürr, Franziska Leonhardt, Gabriele Prinz, Reinhard Marks, Ulrike Gerlach, Maike Hofmann, Paul Fisch, Jürgen Finke, Hanspeter Pircher, Robert Zeiser   +11 more
doaj   +1 more source

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease

Haematologica, 2015
Effective immunosuppression is mandatory to prevent graft-versus-host disease and to achieve a successful clinical outcome of hematopoietic stem cell transplantation.
Isabelle Laverdière, Chantal Guillemette, Ryad Tamouza, Pascale Loiseau, Regis Peffault de Latour, Marie Robin, Félix Couture, Alain Filion, Marc Lalancette, Alan Tourancheau, Dominique Charron, Gérard Socié, Éric Lévesque   +12 more
doaj   +1 more source

Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect

Haematologica, 2020
Acute graft-versus-host disease causes significant mortality in patients undergoing allogeneic hematopoietic cell transplantation. Immunosuppressive treatment for graft-versus-host disease can impair the beneficial graft-versus-leukemia effect and ...
Eileen Haring, Franziska M. Uhl, Geoffroy Andrieux, Michele Proietti, Alla Bulashevska, Barbara Sauer, Lukas M. Braun, Enrique de Vega Gomez, Philipp R. Esser, Stefan F. Martin, Dietmar Pfeifer, Marie Follo, Annette Schmitt-Graeff, Joerg Buescher, Justus Duyster, Bodo Grimbacher, Melanie Boerries, Erika L. Pearce, Robert Zeiser, Petya Apostolova   +19 more
doaj   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. [PDF]

PLoS ONE, 2013
Programmed cell death ligand-1 (PD-L1/CD274) is an immunomodulatory molecule involved in cancer and complications of bone marrow transplantation, such as graft rejection and graft-versus-host disease.
Heevy Al-Chaqmaqchi, Behnam Sadeghi, Manuchehr Abedi-Valugerdi, Sulaiman Al-Hashmi, Mona Fares, Raoul Kuiper, Joachim Lundahl, Moustapha Hassan, Ali Moshfegh   +8 more
doaj   +1 more source

Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation [PDF]

, 2012
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marrow transplantation (BMT) characterized by an autoimmune-type reaction in various organs.
Yumi Matsuzaki, Yoko Ogawa, Shigeto Shimmura, Yo Mabuchi, Sadafumi Suzuki, Yutaka Kawakami, Shinichiro Okamoto, Hideyuki Okano, Takaaki Inaba, Satoru Morikawa, Saori Yaguchi, Kazuo Tsubota, Tomonori Yaguchi   +12 more
core  

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source